Melior Enters Research Collaboration with AstraZeneca
EXTON, Pa. (Business Wire EON/PRWEB ) August 19, 2008 --
Melior Discovery, Inc. announced today that it has signed an agreement
with AstraZeneca PLC under which Melior’s
in-vivo theraTRACE® indications
discovery platform will be used to evaluate the therapeutic activity of
selected AstraZeneca compounds.
“Our agreement represents a significant
opportunity for Melior to deliver value to AstraZeneca through the
application of our unique and innovative in vivo testing platform,”
said Andrew Reaume, PhD, President and CEO of Melior. ”We
look forward to a productive collaboration.”
Melior Discovery Overview
Melior Discovery is leading the transformation of drug repositioning
with its unique theraTRACE platform of multiplexed in vivo
models. Melior is using theraTRACE to both build an internal
pipeline of development candidates as well as sharing this capability
with pharmaceutical and biotechnology company partners. In the former
case, Melior identifies and develops “privileged”
compounds that have been discontinued by other companies for lack of
efficacy in their original indications. Melior is also able to identify
appropriate compounds for repositioning by leveraging a close working
relationship with the renowned medicinal chemist, Dr. Christopher
Lipinski. In its partnered arrangements, Melior offers pharmaceutical
partners an approach to expand their late-stage pipelines with safe,
high-quality drug candidates
Melior Discovery is located in Exton, PA.
See the original story at: http://eon.businesswire.com/releases/melior/astrazeneca/prweb1226754.htm
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/Q291cC1FbXB0LVRoaXItSG9yci1Db3VwLVNpbmctWmVybw==
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
